Later studies on NSCLC demonstrated that α11β1 signaling leads to the upregulation of lysyl oxidase like-1 (LOXL1) and, subsequently, increased collagen crosslinking, stromal stiffness, and tumor growth and progression (13, 14). The gene discussed is LOXL1; the disease is neoplasm.